Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer

Clinical utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer

The advent of rationally targeted therapies such as small-molecule tyrosine kinase inhibitors (TKIs) has considerably transformed the therapeutic management of a subset of patients with non-small cell lung cancer (NSCLC) harboring defined molecular abnormalities. When such genetic molecular alterati...

Full description

Bibliographic Details
Main Authors: Vincent eFaugeroux, Emma ePailler, Nathalie eAuger, Meilissa eTaylor, Françoise eFarace
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-11-01
Series:Frontiers in Oncology
Subjects:
targeted therapy
Circulating Tumor Cells (CTCs)
predictive biomarker
ALK rearrangement
non-small-cell lung cancer (NSCLC)
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00281/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00281/full

Similar Items